Radionuclide Therapy

Iodine-131 is considered to be the treatment of choice in many patients with Graves’ disease. The most common side effect of radioactive iodine (RAI) treatment is:

Transient increase in tracer uptake in responding metastases in the early months after chemotherapy/hormone therapy for breast and prostate cancer is called:

According to the Society of Nuclear Medicine “SNM Procedure Guideline for Therapy of Thyroid Disease with I-131 (Sodium Iodide),” typically administered activity for treatment of presumed thyroid cancer in the neck or mediastinal lymph nodes is in the range:

What is the predominant toxicity of radioisotopes used in the treatment of bone metastases?

An ultimate treatment for patients who are nonresponsive to or cannot tolerate other available therapies for a particular illness and whose prognosis is often poor is called:

Which of the following time is advised for patients treated with 1-131 to delay conception after treatment?

Samarium-153 (Quadramet) is a therapeutic radiopharmaceutical used to treat:

To reduce radiation exposure to the patient undergoing radioactive iodine (RAI) treatment, all of the following recommendations will be helpful EXCEPT:

The general pretreatment requirements for adult qualifying for therapy with I-131 metaiodobenzylguanidine (MIBG) include the following EXCEPT:

The form of targeted radionuclide therapy that uses a monoclonal antibody to deliver localized radiation is called: